We have been watching the dialogue about hemp legislation being presented in States and at the Federal level and there are quite a few concerns.
There are people who are also working to protect your best interest and we recommend that you pay attention to their opinions and for clear and source information. They are Jason Lauve, Melissa Mentele, Veronica Carpio, Richard Rose, David Barhorst, and Steve Sarich. There are others and we will share their information soon.
Here is an article to look at to start the conversation for now. We will be reporting on our research in the next few days.
Cannabis Stock Report: Marijuana Stocks Mixed As Epidiolex Renews Questions Over GW Pharmaceuticals Corporate Practices
By Brandon A. Dorfman
APR 23, 2018
The North American Marijuana Index closed mixed on Friday, despite renewed bullishness in the pot stock sector over FDA committee approvals for GW Pharmaceuticals (NASDAQ:GWPH) cannabidiol drug Epidiolex. Share prices for cannabis own “Big Pharma” company rose ten percent week, though favorable headlines failed to stir shareholders into an industry-wide rally. To the contrary, widespread attention should lead to renewed questions about the drug’s possible cataclysmic effect on the sector as well as GW’s less than savory business practices.
Last year Leafly reported that GW Pharmaceuticals and its American subsidiary Greenwich BioSciences attempted to secretly push proprietary CBD bills through the state legislatures of South Dakota and Nebraska. Lobbyists pushed the bills in hopes of making Epidiolex the exclusive CBD drug available in those states.
“SB 95 will block all current and readily-available CBD options for South Dakota’s children,” Melissa Mentele, the chairperson of New Approach South Dakota, the state’s main cannabis reform group told Leafly at the time. “It will make Epidiolex the only option. As we know, one medicine does not work for all patients. We can’t take away options for these catastrophically ill children and their families.”
Moreover, as Project CBD reiterated in a statement on the subject last fall, should CBD become a prescription-only drug it would be to the detriment to thousands of Americans who would no longer be able to afford it outright.